Literature DB >> 28179647

Narcolepsy.

Birgitte R Kornum1,2, Stine Knudsen3, Hanna M Ollila4, Fabio Pizza5,6, Poul J Jennum2, Yves Dauvilliers7, Sebastiaan Overeem8,9.   

Abstract

Narcolepsy is a chronic sleep disorder that has a typical onset in adolescence and is characterized by excessive daytime sleepiness, which can have severe consequences for the patient. Problems faced by patients with narcolepsy include social stigma associated with this disease, difficulties in obtaining an education and keeping a job, a reduced quality of life and socioeconomic consequences. Two subtypes of narcolepsy have been described (narcolepsy type 1 and narcolepsy type 2), both of which have similar clinical profiles, except for the presence of cataplexy, which occurs only in patients with narcolepsy type 1. The pathogenesis of narcolepsy type 1 is hypothesized to be the autoimmune destruction of the hypocretin-producing neurons in the hypothalamus; this hypothesis is supported by immune-related genetic and environmental factors associated with the disease. However, direct evidence in support of the autoimmune hypothesis is currently unavailable. Diagnosis of narcolepsy encompasses clinical, electrophysiological and biological evaluations, but simpler and faster procedures are needed. Several medications are available for the symptomatic treatment of narcolepsy, all of which have quite good efficacy and safety profiles. However, to date, no treatment hinders or slows disease development. Improved diagnostic tools and increased understanding of the pathogenesis of narcolepsy type 1 are needed and might lead to therapeutic or even preventative interventions.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28179647     DOI: 10.1038/nrdp.2016.100

Source DB:  PubMed          Journal:  Nat Rev Dis Primers        ISSN: 2056-676X            Impact factor:   52.329


  30 in total

Review 1.  Neurobiological and immunogenetic aspects of narcolepsy: Implications for pharmacotherapy.

Authors:  Steven T Szabo; Michael J Thorpy; Geert Mayer; John H Peever; Thomas S Kilduff
Journal:  Sleep Med Rev       Date:  2018-11-08       Impact factor: 11.609

2.  Efficacy of THN102 (a combination of modafinil and flecainide) on vigilance and cognition during 40-hour total sleep deprivation in healthy subjects: Glial connexins as a therapeutic target.

Authors:  Fabien Sauvet; Mégane Erblang; Danielle Gomez-Merino; Arnaud Rabat; Mathias Guillard; Dominique Dubourdieu; Hervé Lefloch; Catherine Drogou; Pascal Van Beers; Clément Bougard; Cyprien Bourrrilhon; Pierrick Arnal; Werner Rein; Franck Mouthon; Francoise Brunner-Ferber; Damien Leger; Yves Dauvilliers; Mounir Chennaoui; Mathieu Charvériat
Journal:  Br J Clin Pharmacol       Date:  2019-09-15       Impact factor: 4.335

3.  Optical probing of orexin/hypocretin receptor antagonists.

Authors:  Shi-Bin Li; Natalie Nevárez; William J Giardino; Luis de Lecea
Journal:  Sleep       Date:  2018-10-01       Impact factor: 5.849

Review 4.  Narcolepsy Type 1 as an Autoimmune Disorder: Evidence, and Implications for Pharmacological Treatment.

Authors:  Lucie Barateau; Roland Liblau; Christelle Peyron; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2017-10       Impact factor: 5.749

Review 5.  Immunotherapy in Narcolepsy.

Authors:  Maria Pia Giannoccaro; Giombattista Sallemi; Rocco Liguori; Giuseppe Plazzi; Fabio Pizza
Journal:  Curr Treat Options Neurol       Date:  2020-01-30       Impact factor: 3.598

Review 6.  pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy.

Authors:  Noeen Sarfraz; David Okuampa; Hannah Hansen; Mark Alvarez; Elyse M Cornett; Juyeon Kakazu; Adam M Kaye; Alan D Kaye
Journal:  Health Psychol Res       Date:  2022-05-30

7.  Impaired histaminergic neurotransmission in children with narcolepsy type 1.

Authors:  Patricia Franco; Yves Dauvilliers; Clara Odilia Inocente; Aurore Guyon; Carine Villanueva; Veronique Raverot; Sabine Plancoulaine; Jian-Sheng Lin
Journal:  CNS Neurosci Ther       Date:  2018-09-17       Impact factor: 5.243

8.  Lag Analysis of Fast fMRI Reveals Delayed Information Flow Between the Default Mode and Other Networks in Narcolepsy.

Authors:  M Järvelä; V Raatikainen; A Kotila; J Kananen; V Korhonen; L Q Uddin; H Ansakorpi; V Kiviniemi
Journal:  Cereb Cortex Commun       Date:  2020-10-10

Review 9.  Review: Vaccine Myth-Buster - Cleaning Up With Prejudices and Dangerous Misinformation.

Authors:  Paul Löffler
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys.

Authors:  Lais F Berro; Eliseu da Cruz Moreira-Junior; James K Rowlett
Journal:  Drug Alcohol Depend       Date:  2021-07-28       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.